Patrick Malone, MD PhD’s Post

Tune in to the SciMed Biotech Podcast with David Feltquate, CMO of Palleon Pharmaceuticals to learn more about the groundbreaking world of cancer treatment. In this episode, we cover: 🌟 The science behind glyco-immune checkpoints and their potential in cancer therapy. 🚀 David's remarkable journey in oncology research, from PD-1 inhibitors to pioneering precision medicine. 🧬 How Palleon Pharmaceuticals is engineering a brighter future for cancer patients with innovative therapies. Visit our website to listen to this exciting episode discussing how cancer research and treatment is being redefined. #cancerresearch #cancercare #oncology

Our video series: The Making of DXd ADC Technology, continues, with a new perspective from our very own Mary Pinder-Schenck, MD. “Compassion That Evolves Treatment” focuses on people with cancer and how their experiences inspire us to create innovative medicines. Don't miss the other videos on our proprietary DXd ADC Technology from Ken Keller and Mark Rutstein. They discuss this targeted approach toward cancer treatment that aims to change the standard of care. #DSProud #ADC #OncologyResearch

"Tumors have evolved ways to block the immune system... Therapies that can block that from happening can prevent the tumor from growing." 🩸🔐 Interested in how cancer treatment works? Join us on the SciMed Biotech Podcast with David Feltquate, Chief Medical Officer at Palleon Pharmaceuticals, as we dive deep into the world of cancer immunotherapy. David’s insights reveal how tumors slyly evade the immune system by using molecules like keys and locks. When these connect, they can deactivate our immune cells. Listen now to learn how groundbreaking therapies are disrupting these evasion tactics, potentially altering the landscape of cancer treatment as we know it. #CancerTreatment #Immunotherapy #Podcast

Today, Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay. “Axlab is a top-5 brand in cancer screening and diagnostics in the Nordics and has delivered impressive sales results. We are excited to sign an agreement with such a successful and fast-moving team. This agreement opens for a systematic sales approach to the Nordic countries and makes the DiviTum TKa assay available for oncology departments and cancer centers,” said Helle Fisker, VP of Commercialization for Biovica. “Bringing the DiviTum TKa assay to the Nordics perfectly fits our organization. We have access to a multi-functional medical network around cancer patients at the hospitals and a deep experience in oncology healthcare processes. The DiviTum TKa assay strengthens our market position further and brings us closer to the goal of delivering patient-centric treatment monitoring,” said Søren Christensen, CEO of Axlab. Read more: https://loom.ly/ay43Vvg #biovicb #biomarker #oncology #investors #precisonmedicine

Working in pharmaceutical R&D, I am continuously reminded about the critical importance of strategic external collaboration. It is the backbone of many of today’s innovations and integral to our success as we aim to deliver life-changing cancer medicines to patients. At AstraZeneca we know that our bold ambition of eliminating cancer as a cause of death cannot be achieved alone. As part of our Oncology R&D clinical strategy, we’re focused on establishing and strengthening cross-academia collaborations with scientific experts and institutions around the world. By combining our capabilities and expertise with other leaders, we’re able to access more data, leverage cutting-edge technologies and accelerate #cancerresearch like never before. Learn more about how we’re fostering collaborative innovation to advance science and redefine cancer care: https://lnkd.in/eyN4HwG4 #cancer

https://lnkd.in/dQM4FfyM Key Insights: • Lung cancer is the leading cause of cancer death worldwide, In 2020, over 2.2 million new lung cancer cases were reported and near around 1.8 million unfortunate fatalities • Detecting lung cancer early is still a big challenge, with 44% of cases being diagnosed at an advanced stage. Shockingly, in 2021, only 5.8% of eligible people in the U.S. got screened for lung cancer Visit Medicoinsights to explore key insights

Raymond F. Vennare & the entire team at Predictive Oncology have made important strides this quarter and set the stage for continued growth - for any investors interested in the #healthcare space, this is an important read from the Proactive editorial desk. #artificialintelligence #cancerresearch #healthcareai

🎙️ Tune in to the latest episode of the Xtalks Life Science Podcast featuring an insightful interview with Yang Liu, Founder, CEO, and CSO; and Abid Ansari, CFO at OncoC4, Inc. 🚀 Learn about the latest advancements in cancer treatment, the challenges in oncology and immunotherapies, and OncoC4's exciting collaborations with BioNTech and Merck! 🎧 Listen to the full episode here: https://buff.ly/3SJ6Kmc #Immunotherapy #TargetedTherapy #PersonalizedMedicine #Oncology #XtalksPodcast

Investor media in Germany – where Vidac Pharma is listed - have started paying attention to the company. In an article called “The oncology therapy race worth billions”, the Finanznachrichten website mentions Vidac as one of three companies that could benefit from a new “Golden Era” for cancer therapy. And in another story, the website identifies Vidac as a takeover candidate after Novartis’s acquisition of Morphosys in February. Look at these two stories here https://shorturl.at/dqtwJ and (in German) here: https://shorturl.at/tJQY7 Vidac Pharma is developing a new class of cancer drugs that reverses the abnormal metabolism common to all cancer cells. While the phenomenon was discovered a hundred years ago, surprisingly, no drugs have been developed to target it. Early results with Vidac’s two drug candidates give hope they can be applied across a wide range of tumors. #biotech #oncology #drugdevelopment #bioscience #cancer

Predictive Oncology Inc. (NASDAQ:POAI) listed a number of recent milestones with the release of its third-quarter results, which also revealed a significant 22% reduction in its net loss. Chairman and CEO Raymond Vennare highlighted the delivery of successful results from its first campaign with Cancer Research Horizons, a subsidiary of the largest independent funder of #cancer research in the world. “In this ground-breaking and validating work, we leveraged our PEDAL platform and capabilities to evaluate their pre-clinical glutaminase inhibitors to predict, with a high degree of accuracy, which cancer types and patient populations are most likely to respond to these compounds, providing actionable information that can inform future clinical development pathways,” Vennare commented in a statement. More at #Proactive #ProactiveInvestors #NASDAQ #POAI #PredictiveOncology http://ow.ly/hN8N1051Pi5